Kathleen Neville, MD

Kathleen NevilleSr. Director, Pediatric Drug Development

Johnson & Johnson

Dr. Kathleen Neville is board certified in pediatrics, pediatric hematology/oncology and clinical pharmacology. Dr. Neville earned her Doctor of Medicine at SUNY HSC-Brooklyn and she holds a Master of Science degree in Clinical Research from Indiana University and a Master’s in Business administration from the Henry W. Bloch School of Management at the University of Missouri-Kansas City in Kansas City, MO.

Dr. Neville has served as Director of Experimental Therapeutics for several Nationally known programs as well as Chief of the Section of Clinical Pharmacology and Toxicology and Co-Director of Precision Medicine at Arkansas Children’s Hospital. She has also served on the pediatric subcommittee of the FDA’s Oncologic Drugs Advisory Committee, the FDA’s Pediatric Advisory Committee and on several special emphasis committees. In addition, Dr. Neville has served as Chair for the American Academy of Pediatrics (AAP) Committee on Drugs. She served as lead author of the AAP’s policy statement on the off-label use of drugs and she has collaborated with investigators across the US and internationally for new agents in pediatric early phase trials.

Dr. Neville has significant clinical trials expertise (e.g., study design, execution, data analysis, holding an IND) as well as translational research experience as it relates to the use of medications in children. She is an expert in pediatric drug development with a focus on early phase trials in pediatric oncology and hematology. She has also maintained an interest in rare diseases and the treatment of pain in children.

Pin It on Pinterest

Scroll to Top